Stay updated on TIL Therapy+Checkpoint Inhibitors in Metastatic Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the TIL Therapy+Checkpoint Inhibitors in Metastatic Ovarian Cancer Clinical Trial page.

Latest updates to the TIL Therapy+Checkpoint Inhibitors in Metastatic Ovarian Cancer Clinical Trial page
- Check2 days agoChange DetectedDifference0.2%
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.4%
- Check16 days agoChange DetectedThe page has undergone significant changes, including the removal of detailed eligibility criteria for a clinical trial involving metastatic renal cell carcinoma and the addition of a new version revision. The principal investigator's name has also been retained.SummaryDifference35%
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.3%
- Check38 days agoChange DetectedThe page has been updated to include information on Clear Cell Renal Cell Carcinoma while removing references to Transitional Cell Carcinoma.SummaryDifference0.2%
- Check67 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
Stay in the know with updates to TIL Therapy+Checkpoint Inhibitors in Metastatic Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TIL Therapy+Checkpoint Inhibitors in Metastatic Ovarian Cancer Clinical Trial page.